Alnylam Pharmaceuticals vs Zimmer Biomet Holdings

Alnylam Pharmaceuticals (ALNY), health care, and Zimmer Biomet Holdings (ZBH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alnylam Pharmaceuticals is worth $21B on the stock market and Zimmer Biomet Holdings $19.3B: Alnylam Pharmaceuticals is valued at 8% more. Alnylam Pharmaceuticals trades at 7.9 times earnings and Zimmer Biomet Holdings at 25.8; operating margins in their latest fiscal years were 13.5% and 13.3%. Over the past year Alnylam Pharmaceuticals's share price has moved -65.4% and Zimmer Biomet Holdings's +13.8%.

Key facts

Alnylam Pharmaceuticals market value
$21B
Zimmer Biomet Holdings market value
$19.3B
Alnylam Pharmaceuticals P/E
7.9
Zimmer Biomet Holdings P/E
25.8
Alnylam Pharmaceuticals revenue
$3.7BFY to 2025-12-31
Zimmer Biomet Holdings revenue
$8.2BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Alnylam Pharmaceuticals vs Zimmer Biomet Holdings: every measure side by side
Measure Alnylam Pharmaceuticals Zimmer Biomet Holdings
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$21Bhigher$19.3Blower
Revenue$3.7Blower$8.2Bhigher
Earnings$313.7Mlower$705.1Mhigher
Employees2,500lower17,000higher
Total assets$5Blower$23.1Bhigher
Valuation
P/E7.9lower25.8higher
P/S5.6higher2.3lower
P/B5.8higher1.5lower
Dividend yield0.00%lower0.95%higher
Profitability
Operating margin13.5%higher13.3%lower
Balance sheet
Net assets$789.2Mlower$12.7Bhigher
Total liabilities$4.2Blower$10.4Bhigher
Total debt—$7.5B
Cash on hand$1.7Bhigher$591.9Mlower
Price change
Today-2.02%lower+0.67%higher
1 year-65.4%lower+13.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Alnylam Pharmaceuticals / Zimmer Biomet Holdings). Who owns ALNY · Who owns ZBH

Further comparisons

Learn

Questions and answers

Which is bigger, Alnylam Pharmaceuticals or Zimmer Biomet Holdings?

By market value, Alnylam Pharmaceuticals is the larger: $21B against $19.3B for Zimmer Biomet Holdings. By revenue in its latest fiscal year, Zimmer Biomet Holdings is the larger: $8.2B against $3.7B for Alnylam Pharmaceuticals.

Which has the higher P/E ratio?

Zimmer Biomet Holdings: 25.8, against 7.9 for Alnylam Pharmaceuticals. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Alnylam Pharmaceuticals: 13.5%, against 13.3% for Zimmer Biomet Holdings. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Zimmer Biomet Holdings: 0.95%, against 0.00% for Alnylam Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Alnylam Pharmaceuticals and Zimmer Biomet Holdings?

In their latest 13F filings, Dodge & Cox team holds both.

Cite this page

Funkfolio, “Alnylam Pharmaceuticals vs Zimmer Biomet Holdings”, data as of 18 November 2026. https://funkfolio.com/compare/alny-vs-zbh

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.